Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.
Romero
Pedro
P
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland. pedro.romero@isrec.unil.ch
Valmori
Danila
D
Pittet
Mikael J
MJ
Zippelius
Alfred
A
Rimoldi
Donata
D
Lévy
Frederic
F
Dutoit
Valérie
V
Ayyoub
Maha
M
Rubio-Godoy
Verena
V
Michielin
Olivier
O
Guillaume
Philippe
P
Batard
Pascal
P
Luescher
Immanuel F
IF
Lejeune
Ferdy
F
Liénard
Danielle
D
Rufer
Nathalie
N
Dietrich
Pierre-Yves
PY
Speiser
Daniel E
DE
Cerottini
Jean-Charles
JC
D000595:Amino Acid Sequence; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D016233:Immunotherapy, Active; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000737:chemistry / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D025941:Protein Interaction Mapping; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013329:Structure-Activity Relationship; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D011948:Receptors, Antigen, T-Cell